A Multi-Center, Open-Label Exploratory Study to Assess Cognitive Function Response to Lifestyle Changes Plus Supplementation in Healthy Adults with Risk Factors Associated with Cognitive Decline

Abstract

PreCODE is a multifaceted protocol that applies lifestyle modifications to improve cognitive decline. NeuroQ is a blend of ingredients that have been individually reported to benefit cognition. The objective of this open-label exploratory study was to evaluate the efficacy of PreCODE with NeuroQ on cognition in healthy adults with risk factors for cognitive decline. Thirty participants ≥45 years at-risk of cognitive decline underwent PreCODE with NeuroQ. Cognitive function was assessed by CNS-Vital Signs (CNS-VS) at 30, 60 and 90 days. Quality of life (QoL), sleepiness, depression, and healthy habits were assessed with the Medical Outcomes Survey, Epworth Sleepiness Scale, Patient Health Questionnaire, and Life Habits Checklist, respectively. There was a 10, 12, and 14% increase in the neurocognitive index percentile scores from screening at Day 30, 60, and 90, respectively (p ≤ 0.01). The CNS-VS domains in psychomotor-, processing-, and motor-speed, complex- and sustained-attention, reaction time, cognitive flexibility, executive function, and working memory improved at Day 90 (p ≤ 0.04). Executive function, cognitive flexibility, processing speed, and working memory, improved by 12, 11, 10, and 7%, respectively, at Day 90. There were improvements in QoL, daytime sleepiness, depression, and lifestyle habits (p ≤ 0.014). NeuroQ was safe and well tolerated. PreCODE with NeuroQ improved cognitive function and QoL in adults at-risk of cognitive decline. Placebo- or comparator-controlled studies are warranted to confirm the effect on cognitive function.